Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-NY129
- Development stage
- Preclinical
- Lead developer
- Norroy Bioscience
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
177Lu-NY129 is an investigational radiopharmaceutical candidate developed by Norroy Bioscience. It is designed to target acid phosphatase 3 (ACP3), also known as prostatic acid phosphatase (PAP), which is highly expressed in prostate cancer cells but virtually absent in most healthy tissues. By conjugating the ACP3-targeting ligand with the beta-emitting radionuclide lutetium-177 (177Lu), the drug selectively delivers targeted radiation to prostate cancer lesions, offering a potential therapeutic and diagnostic (theranostic) alternative or complement to PSMA-targeted radioligand therapies.
- Other names
- 68Ga/177Lu-NY129Lu-177-NY129Lu177-NY129Lu 177-NY129lutetium (177Lu) NY129lutetium-177 NY129lutetium177 NY129lutetium 177 NY129
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on 177Lu-NY129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-NY129.